To further examine whether the role of CDK6 in lenvatinib resistance is clinically relevant in HCC, we have examined CDK6 expression in tumors of seven HCC patients who received lenvatinib treatment. This evidence concerns the gene CDK6 and hepatocellular carcinoma.